日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

强效胆固醇酯转移蛋白抑制剂奥比塞曲匹对心血管疾病患者p-tau217水平的影响

Davidson, Michael H; Szarek, Michael; Scheltens, Philip; Vijverberg, Everard; Hsieh, Andrew; Ditmarsch, Marc; Kling, Douglas; Curcio, Danielle; Nicholls, Stephen J; Ray, Kausik K; Cummings, Jeffrey L; Kastelein, John Jp

The emerging role of CETP inhibition in the prevention of Alzheimer's disease

CETP抑制在预防阿尔茨海默病中的新兴作用

Davidson, Michael H; Hsieh, Andrew; de Kleer, Mathijs; Szarek, Michael S; Scheltens, Philip; Vijverberg, Everard; Johnson, Adam; Ditmarsch, Marc; Kastelein, John J P

Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

新型降胆固醇药物:2/3期临床试验安全性评估能否预测心血管事件结果试验疗效?

Shear, Charles; Davidson, Michael H; Ditmarsch, Marc; Kastelein, John J P; Szarek, Michael

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis

胆固醇酯转移蛋白 (CETP) 活性降低与痴呆风险:一项孟德尔随机化分析

Schmidt, Amand F; Davidson, Michael H; Ditmarsch, Marc; Kastelein, John J; Finan, Chris

Correction: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysis

更正:胆固醇酯转移蛋白 (CETP) 活性降低与痴呆风险:一项孟德尔随机化分析

Schmidt, Amand F; Davidson, Michael H; Ditmarsch, Marc; Kastelein, John J; Finan, Chris

CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis

CETP 和 SGLT2 抑制剂联合治疗可改善血糖控制:一项 2x2 析因孟德尔随机化分析

Khomtchouk, Bohdan B; Sun, Patrick; Maggio, Zane A; Ditmarsch, Marc; Kastelein, John J P; Davidson, Michael H

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

奥比曲匹作为稳定他汀类药物治疗的辅助药物在日本受试者中的疗效:一项随机II期试验的结果

Harada-Shiba, Mariko; Davdison, Michael H; Ditmarsch, Marc; Hsieh, Andrew; Wuerdeman, Erin; Kling, Douglas; Nield, Annie; Dicklin, Mary R; Nakata, Akitaka; Sueyoshi, Atsushi; Kuroyanagi, Satoshi; Kastelein, John J P

Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials

与以往的胆固醇酯转移蛋白抑制剂相比,奥比曲匹布具有更优的理化和药代动力学特性:非人灵长类动物研究和临床试验结果的综合总结

Nicholls, Stephen J; Nelson, Adam J; Kastelein, John J P; Ditmarsch, Marc; Hsieh, Andrew; Johnson, Judith; Curcio, Danielle; Kling, Douglas; Kirkpatrick, Carol F; Davidson, Michael H

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

比较接受胆固醇酯转移蛋白抑制剂治疗的血脂异常患者的低密度脂蛋白胆固醇方程

Martin, Seth S; Ditmarsch, Marc; Simmons, Mark; Alp, Nicholas; Turner, Traci; Davidson, Michael H; Kastelein, John J P

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Obicetrapib 联合依折麦布作为高强度他汀类药物治疗的辅助疗法:一项随机 2 期试验

Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, Adam J Nelson, Douglas Kling, Andrew Hsieh, Danielle L Curcio, Kevin C Maki, Michael H Davidson, Stephen J Nicholls